Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
NCT03323151Phase 2Completed
- Sponsor
- PrECOG
- Start
- Aug 2018
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in mantle cell lymphoma (MCL), sponsored by PrECOG. Started Aug 2018; status: completed.
02
Drugs
ixazomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03323151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323151.